Are you Dr. Rivkin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1221 Madison St
Seattle, WA 98104Phone+1 206-386-2323Fax+1 206-386-2729
Summary
- Dr. Saul Rivkin, MD is a hematologist in Seattle, Washington. He is currently licensed to practice medicine in Washington. He is affiliated with Swedish Cherry Hill Campus, St. Anne Hospital, and Providence Swedish Edmonds.
Education & Training
- University of New Mexico School of MedicineResidency, Internal Medicine, 1970 - 1971
- University of New Mexico School of MedicineResidency, Internal Medicine, 1965 - 1968
- University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1964 - 1965
- University of Washington School of MedicineClass of 1964
Certifications & Licensure
- WA State Medical License 1965 - 2022
Clinical Trials
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 11 citationsPhase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patientsSaul E. Rivkin, James Moon, Desiree Iriarte, Erik Bailey, Heather L. Sloan
International Journal of Gynecological Cancer. 2019-01-29 - 19 citationsA phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavityMihaela C. Cristea, Paul Frankel, Timothy W. Synold, Saul E. Rivkin, Dean Lim
Cancer Chemotherapy and Pharmacology. 2019-01-08 - 17 citationsColorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions.David Chu, Michael A. Hussey, David S. Alberts, Frank L. Meyskens, Cecilia M. Fenoglio-Preiser
Clinical Colorectal Cancer. 2011-12-01
Press Mentions
- Olaparib Tablet Safe in Pretreated Ovarian Cancer PatientsSeptember 10th, 2014
Grant Support
- Southwest Oncology GroupNational Cancer Institute1985–2012
- Small Instrumentation GrantNational Cancer Institute1993
Professional Memberships
- Member